An integrative pathway-based clinical-genomic model for cancer survival prediction

Statistics and Probability Letters

Volumn 80, Issue 17-18, 2010, Pages 1313-1319

  Chen, Xi ^a   Wang, Lily ^a   Ishwaran, Hemant ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Gene expression; Microarrays; Pathway analysis; Random survival forests; Survival prediction

Indexed keywords

EID: 77954541112     PISSN: 01677152     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spl.2010.04.011     Document Type: Article

References (42)

1. Alon U., Barkai N., Notterman D.A., Gish K., Ybarra S., Mack D., Levine A.J. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 1999, 96:6745-6750.
2. Alter O., Brown P.O., Botstein D. Singular value decomposition for genome-wide expression data processing and modeling. Proc. Natl. Acad. Sci. USA 2000, 97:10101-10106.
3. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., et al. Gene ontology: tool for the unification of biology. Gene Ontology Consortium. Nat. Genet. 2000, 25:25-29.
4. Bair E., Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004, 2:511-522.
5. Bair E., Hastie T., Paul D., Tibshirani R. Prediction by supervised principal components. J. Amer. Statist. Assoc. 2006, 101:119-137.
6. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., Lin L., Chen G., Gharib T.G., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002, 8:816-824.
7. Bild A.H., Potti A., Nevins J.R. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer 2006, 6:735-741.
8. Binder H., Schumacher M. Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models. BMC Bioinform. 2008, 9:14.
9. Breiman L. Random forests. Mach. Learn. 2001, 45:5-32.
10. Chen X., Wang L., Smith J.D., Zhang B. Supervised principal component analysis for gene set enrichment of microarray data with continuous or survival outcomes. Bioinformatics 2008, 24:2474-2481.
11. Chen X., Wang L. Integrating biological knowledge with gene expression profiles for survival prediction of cancer. J. Comput. Biol. 2009, 16:265-278.
12. Datta S., Datta S. Comparisons and validation of statistical clustering techniques for microarray gene expression data. Bioinformatics 2003, 19:459-466.
13. Datta S., Le-Rademacher J., Datta S. Predicting patient survival from microarray data by accelerated failure time modeling using partial least squares and LASSO. Biometrics 2007, 63:259-271.
14. Ein-Dor L., Kela I., Getz G., Givol D., Domany E. Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics 2005, 21:171-178.
15. Gagliardi A., Collins D.C. Inhibition of angiogenesis by antiestrogens. Cancer Res. 1993, 53:533-535.
16. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1:11-21.
17. Harrell F.E., Califf R.M., Pryor D.B., Lee K.L., Rosati R.A. Evaluating the yield of medical tests. J. Am. Med. Assoc. 1982, 247:2543-2546.
18. Hastie T., Tibshirani R. Efficient quadratic regularization for expression arrays. Biostatistics 2004, 5:329-340.
19. Ishwaran H., Kogalur U.B., Blackstone E.H., Lauer M.S. Random survival forests. Ann. Appl. Stat. 2008, 2:841-860.
20. Ishwaran H., Kogalur U.B. Random survival forests for R. Rnews 2007, 7/2:25-31.
21. Ishwaran H. Variable importance in binary regression trees and forests. Electron. J. Stat. 2007, 1:519-537.
22. Kanehisa M., Goto S., Kawashima S., Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res. 2002, 30:42-46.
23. Lee E., Chuang H.Y., Kim J.W., Ideker T., Lee D. Inferring pathway activity toward precise disease classification. PLoS Comput. Biol. 2008, 4(11):e1000217.
24. Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., Gillet C., Ellis P., Ryder K., et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genom. 2008, 9:239.
25. Mandlekar S., Hebbar V., Christov K., Kong A.N.T. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res. 2000, 60:6601-6606.
26. Mandlekar S., Kong A.N.T. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001, 6:469-477.
27. Manoli T., Gretz N., Grone H.J., Kenzelmann M., Eils R., Brors B. Group testing for pathway analysis improves comparability of different microarray datasets. Bioinformatics 2006, 22:2500-2506.
28. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102:13550-13555.
29. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., et al. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
30. Nguyen D.V., Rocke D.M. Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 2002, 18:1625-1632.
31. Obrero M., Yu D.V., Shapiro D.J. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J. Biol. Chem. 2002, 277:45695-45703.
32. Ogawa Y., Murata Y., Nishioka A., Inomata T., Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998, 351. 725-725.
33. Pandolfi P.P. Breast cancer-loss of PTEN predicts resistance to treatment. N. Engl. J. Med. 2004, 351:2337-2338.
34. Park M.Y., Hastie T. L-1-regularization path algorithm for generalized linear models. J. Roy. Stat. Soc. B 2007, 69:659-677.
35. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
36. Ryden L., Stendahl M., Jonsson H., Emdin S., Bengtsson N., Landberg G. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res. TR 2005, 89:135-143.
37. Segal M.R. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited. Biostatistics 2006, 7:268-285.
38. Tibshirani R., Walther G., Hastie T. Estimating the number of clusters in a data set via the gap statistic. J. Roy. Stat. Soc. B 2001, 63:411-423.
39. Tomfohr J., Lu J., Kepler T.B. Pathway level analysis of gene expression using singular value decomposition. BMC Bioinform. 2005, 6:225.
40. Wang D., Dubois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
41. Wang L., Zhang B., Wolfinger R.D., Chen X. An integrated approach for the analysis of biological pathways using mixed models. PLoS Genet. 2008, 4:e1000115.
42. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.